I found the attached picture showing the drug development pipeline for Alzheimers drugs.

A lot of the CGS investor presentation is based on their Japanese partner, Esai, and the newly FDA approved (albeit controversial) drug Aducanamab. If CGS has a distinctive offering, then the potential demand will take off. This is a point the CGS CEO made recently - once a first drug is approved, the development pipeline gets turbocharged. (Matt is making this point as I type!).

So the near-term metric to track for CGS is do they sign up to more companies to support their clinical trial work.

Disc: Held IRL (I took an initial position earlier this week. Spec buy.)